Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740779 · ClinicalTrials.gov registry record · Phase 2
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
A Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT00740779 is a Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 153 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT00740779, a Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Silodosin 8 mg
- DRUG Silodosin 4 mg
Study Locations (20)
New York
- Watson Investigational Site - Garden City
- Watson Investigational Site - Kingston
- Watson Investigational Site - New York
- Watson Investigational Site - Poughkeepsie
Georgia
- Watson Investigational Site - Columbus
- Watson Investigational Site - Roswell
Massachusetts
- Watson Investigational Site - Boston
- Watson Investigational Site - Watertown
Oklahoma
- Watson Investigational Site - Bethany
- Watson Investigational Site - Edmond
California
- Watson Investigational Site - San Diego
Colorado
- Watson Investigational Site - Denver
Indiana
- Watson Investigational Site - Jeffersonville
Iowa
- Watson Investigational Site - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740779
The ClinicalTrials.gov registry entry for NCT00740779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00740779 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00740779 about?
NCT00740779 is a clinical study titled "Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.". The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of sil...
What is the current status of trial NCT00740779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2008-09. Estimated completion is 2009-10.
What conditions does trial NCT00740779 study?
This clinical trial studies the following conditions: Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
What interventions are being tested in trial NCT00740779?
The interventions under investigation include: Placebo (DRUG), Silodosin 8 mg (DRUG), Silodosin 4 mg (DRUG).
Who is sponsoring clinical trial NCT00740779?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00740779 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.